It seems like GLP-1 giants Novo Nordisk and Eli Lilly are locked in a fierce bat...
An interim analysis of Merck’s TrilynX study, involving patients with unresected...
Hikma, a generics manufacturer headquartered in London, has reached an agreement...
Japanese pharmaceutical company Takeda has granted rights to Indian firms Cipla ...
An experimental medication has demonstrated potential as an aid for certain peop...
Gilead Sciences (GILD.O) announced that in a late-stage trial, its injectable tr...
California health technology firm Evidation is making its app for logging sympto...
A panel of experts advising the Food and Drug Administration announced earlier t...
Initially thought of as a potential game-changer for metabolic-associated steato...
Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show ...
Pfizer’s gene therapy for Duchenne muscular dystrophy failed to improve motor fu...
The FDA has accepted Eisai’s application for a monthly intravenous maintenance d...
Zealand Pharma has disclosed that Boehringer Ingelheim has published findings fr...
In a nuclear medicine surge, industry leader Orano Med has selected the U.S. as ...
The FDA’s advisory committee has raised concerns about Eli Lilly’s Alzheimer’s d...
An end is drawing close for Illumina’s multibillion-dollar pursuit of Grail. The...
